Moderated by a user called PlanetMedicines for a platform called Psychedelic Mental Health? Can you even believe it? What a time to be alive! I’d love to answer all the questions you must have!
The Reagan-Udall Foundation for the FDA, in collaboration with the FDA, is hosting a hybrid public workshop on "Understanding Current Use of Ketamine for Emerging Areas of Therapeutic Interest." Ketamine is a Schedule III controlled substance that is FDA-approved for induction and maintenance of general anesthesia. Although ketamine is not approved for the treatment of conditions such as depression or
chronic pain, there has been increased interest in it's use for these types of conditions.
This public workshop will explore topics such as the scope of ketamine use, including approved products and compounded products, for these emerging areas of therapeutic interest; potential safety concerns; and online promotion of and access to ketamine.
Speakers will include clinicians, academic researchers, and federal partners. (No psychotherapists or psychedelic therapists are scheduled to speak.)
“After assessing the semantic similarity between 15,000 reports linked to the use of 165 psychoactive substances with 625 NDE {Near Death Experience} narratives, we determined that the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine consistently resulted in reports most similar to those associated with NDEs. Ketamine was followed by Salvia divinorum and a series of serotonergic psychedelics, including the endogenous serotonin 2A receptor agonist N,N-Dimethyltryptamine (DMT). This similarity was driven by semantic concepts related to consciousness of the self and the environment, but also by those associated with the therapeutic, ceremonial and religious aspects of drug use. Our analysis sheds light on the long-standing link between certain drugs and the experience of “dying“, suggests that ketamine could be used as a safe and reversible experimental model for NDE phenomenology, and supports the speculation that endogenous NMDA antagonists with neuroprotective properties may be released in the proximity of death.”
(Neurochemical models of near-death experiences: A large-scale study based on the semantic similarity of written reports, Martial, et al, 2019).
Here ketamine, like DMT, is hypothesized to act on similar receptors to form similar brainwaves, with similar subjective experiences related to proximity to death.
Experiences of Awe Mediate Ketamine's Antidepressant Effects: Findings From a Randomized Controlled Trial in Treatment-Resistant Depression (Aepfelbacher, et al, 2024) https://pubmed.ncbi.nlm.nih.gov/38726038/
“ Ketamine infusion strongly induced heightened feelings of awe, and these experiences consistently mediated depression outcomes over a 1- to 30-day period, unlike general dissociative side effects. The specific awe-inspiring properties of ketamine may contribute to its antidepressant effects.”
Organizing our next round of ketamine therapy training for clinicians and non-clinician guides / trip sitters. Meeting 8 hours per week, this practicum includes 12 experiences with racemic ketamine in various routes of administration, 12 sessions of sitting with someone else under the medicine, 12 hours of didactic training, 12 hours of integration, 12 hours of individual clinical supervision totaling 96 hours of practical experience upon completion of all 12 modules.
Medical clearance by a prescribing clinician licensed in your home state or locality required.
The Psychedelic Institute of Mental Health & Family Therapy is located in Palm Springs, California. Practicum is held online 2 evenings per week, 3.5 hours each evening from 6-9:30pm PST, with an optional in-person retreat weekend.
Practicum Fee: $600 per person per 8 hour weekly module
Moderated by a user called PlanetMedicines for a platform called Psychedelic Mental Health? Can you even believe it? What a time to be alive! I’d love to answer all the questions you must have!
See also - https://psychedelicmentalhealth.net/ketamine-therapy-descriptions-descripciones-de-la-terapia-con-ketamina/
See also: Neural correlates and subjective experiences in meditation vs psychedelics, including ketamine (Preliminary Lit Review) https://psychedelicmentalhealth.net/neural-correlates-subjective-experiences-meditation-psychedelics-ketamine-psychotherapy/
The Reagan-Udall Foundation for the FDA, in collaboration with the FDA, is hosting a hybrid public workshop on "Understanding Current Use of Ketamine for Emerging Areas of Therapeutic Interest." Ketamine is a Schedule III controlled substance that is FDA-approved for induction and maintenance of general anesthesia. Although ketamine is not approved for the treatment of conditions such as depression or chronic pain, there has been increased interest in it's use for these types of conditions. This public workshop will explore topics such as the scope of ketamine use, including approved products and compounded products, for these emerging areas of therapeutic interest; potential safety concerns; and online promotion of and access to ketamine.
Speakers will include clinicians, academic researchers, and federal partners. (No psychotherapists or psychedelic therapists are scheduled to speak.)
See the Full Agenda Review the Slides View Speaker Bios
“After assessing the semantic similarity between 15,000 reports linked to the use of 165 psychoactive substances with 625 NDE {Near Death Experience} narratives, we determined that the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine consistently resulted in reports most similar to those associated with NDEs. Ketamine was followed by Salvia divinorum and a series of serotonergic psychedelics, including the endogenous serotonin 2A receptor agonist N,N-Dimethyltryptamine (DMT). This similarity was driven by semantic concepts related to consciousness of the self and the environment, but also by those associated with the therapeutic, ceremonial and religious aspects of drug use. Our analysis sheds light on the long-standing link between certain drugs and the experience of “dying“, suggests that ketamine could be used as a safe and reversible experimental model for NDE phenomenology, and supports the speculation that endogenous NMDA antagonists with neuroprotective properties may be released in the proximity of death.” (Neurochemical models of near-death experiences: A large-scale study based on the semantic similarity of written reports, Martial, et al, 2019).
Here ketamine, like DMT, is hypothesized to act on similar receptors to form similar brainwaves, with similar subjective experiences related to proximity to death.
More here— https://psychedelic-institute-of-mental-health.ghost.io/does-the-psychedelic-experience-matter/
Experiences of Awe Mediate Ketamine's Antidepressant Effects: Findings From a Randomized Controlled Trial in Treatment-Resistant Depression (Aepfelbacher, et al, 2024) https://pubmed.ncbi.nlm.nih.gov/38726038/
“ Ketamine infusion strongly induced heightened feelings of awe, and these experiences consistently mediated depression outcomes over a 1- to 30-day period, unlike general dissociative side effects. The specific awe-inspiring properties of ketamine may contribute to its antidepressant effects.”
Ketamine’s Role in Spirituality: How One Synthetic Drug Catalyzes a Natural Experience (Woods, 2020)
It brings up a player for me that plays the audio. I’ll find another link, tho!
February 2024: **Ketamine-Assisted Psychotherapy & Support Practicum **
Organizing our next round of ketamine therapy training for clinicians and non-clinician guides / trip sitters. Meeting 8 hours per week, this practicum includes 12 experiences with racemic ketamine in various routes of administration, 12 sessions of sitting with someone else under the medicine, 12 hours of didactic training, 12 hours of integration, 12 hours of individual clinical supervision totaling 96 hours of practical experience upon completion of all 12 modules.
Medical clearance by a prescribing clinician licensed in your home state or locality required.
The Psychedelic Institute of Mental Health & Family Therapy is located in Palm Springs, California. Practicum is held online 2 evenings per week, 3.5 hours each evening from 6-9:30pm PST, with an optional in-person retreat weekend.
Practicum Fee: $600 per person per 8 hour weekly module